Tristel Plc TSTL
LSE · United Kingdom · Health Technology
GBp 405.00-5.00 (-1.22%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The United Kingdom's FTSE 100 index has recently faced downward pressure, influenced by weak trade data from China and a sluggish recovery in its economy, impacting companies with strong ties to Chinese markets. Amidst these challenges, identifying undervalued stocks can be crucial for investors seeking potential opportunities; such stocks may offer significant growth potential if their intrinsic value is indeed higher than current market prices.
The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index experiencing declines due to weak trade data from China, highlighting global economic interdependencies. As investors navigate these turbulent times, identifying stocks that are trading below their fair value could present opportunities for those looking to strengthen their portfolios amidst broader market fluctuations.
Parker Laboratories and Tristel plc will co-sponsor an APIC Theater presentation at APIC26 featuring three clinicians who will share real-world experience implementing Tristel ULT™, a chlorine dioxide (ClO₂) foam for high-level disinfection (HLD) of ultrasound probes.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.